← All grants

Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)

National Institutes of Health · Opportunity PAR-25-096

Deadline November 17, 2026 69 days left
Award range Up to $200k
Total program funding $200k
PostedNovember 18, 2024

Who can apply

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

About this opportunity

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.

Award history — this exact opportunity

NIH RePORTER lists 9 funded awards under PAR-25-096 across 9 organizations.

Awards by fiscal year 2026: 9
Award size (min / median / max) $179k / $408k / $440k

Total award obligations, not per-year amounts.

Recent awardees include: UNIVERSITY OF CALIFORNIA BERKELEY, UNIVERSITY OF NEBRASKA MEDICAL CENTER, UNIVERSITY OF TEXAS AT AUSTIN, JOHNS HOPKINS UNIVERSITY, UNIVERSITY OF MINNESOTA, KAISER FOUNDATION RESEARCH INSTITUTE, AUGUSTA UNIVERSITY, UT SOUTHWESTERN MEDICAL CENTER.

Source: NIH RePORTER, matched on the exact opportunity number. NIH publishes success rates by institute and activity code — source.

Portfolio context — this listing covers more than this opportunity

This opportunity is funded under Assistance Listing 93.121 (“Oral Diseases and Disorders Research”), a broad federal program that made about 300 new awards per year over the last five fiscal years (median award $438k). Those figures describe that whole portfolio — not this specific solicitation, so we don't show them as if they were this opportunity's track record.

Applicant counts per solicitation are not published by any federal agency — no one can honestly sell you that number. NIH publishes success rates by institute and activity code — source.

Apply on grants.gov →

Don't want to hunt for grants like this one? Get free deadline alerts for your state and focus areas.

Consultant or grant writer? See the client-ready Opportunity Brief for this grant — actual award sizes vs. the advertised ceiling, who wins, printable "prepared for your client" version.

Similar grants still open